Quanterix Corporation’s Chief Financial Officer reported a routine share adjustment related to equity compensation. On 12/15/2025, 229 shares of common stock were withheld by Quanterix at a price of $7.41 per share to cover tax obligations that arose when 777 restricted stock units (RSUs) vested. After this tax withholding, the officer beneficially owns 85,977 shares of Quanterix common stock, which includes 84,652 RSUs. This filing reflects administrative handling of taxes on vested stock awards rather than an open-market purchase or sale.
Quanterix Corp reported an insider equity transaction by its President & CEO and Director on 12/15/2025. The filing shows that 1,242 shares of common stock were withheld by Quanterix solely to cover tax obligations that arose when 3,722 restricted stock units (RSUs) vested. This is recorded as a disposition at a price of $7.41 per share for reporting purposes.
Following this tax withholding event, the reporting person beneficially owned 508,704 shares of Quanterix common stock, which includes 212,123 RSUs. The transaction was filed as a Form 4 for a single reporting person in their roles as both Director and President & CEO.
Quanterix Corp (QTRX) director files initial ownership report showing no holdings. A reporting person serving as a director of Quanterix Corporation has filed an initial Form 3 disclosing their beneficial ownership status as of 11/24/2025. The filing indicates that the director has no non-derivative securities beneficially held, with the amount reported as 0.00 shares held directly. The table for derivative securities is also blank, implying there are no options, warrants, or other derivative positions reported at this time. This is a routine disclosure required when an individual becomes an insider under U.S. securities rules.
Quanterix Corp (QTRX) reported a new equity award to one of its directors. On November 20, 2025, the director acquired 46,727 shares of common stock through a grant of restricted stock units (RSUs), reported as an acquisition in a Form 4 filing. Following this grant, the director beneficially owns 46,727 shares directly.
The RSUs vest in three equal installments. One-third of the total shares vest on each of November 20, 2026, November 20, 2027 and November 20, 2028, provided the director continues to provide service to Quanterix on each vesting date. This filing reflects routine director equity compensation rather than an open‑market purchase or sale.
Quanterix Corporation (QTRX) reported a new stock option grant to its Executive Chair and Director. On 11/20/2025, the insider acquired stock options to purchase 70,091 shares of Quanterix common stock at an exercise price of $5.91 per share. These options expire on 11/20/2035.
The options vest monthly over two years in 24 equal installments, as long as the Executive Chair continues providing service to Quanterix on each vesting date. Following this transaction, the reporting person beneficially owns 70,091 derivative securities directly.
Quanterix Corporation’s Chief Financial Officer reported a routine equity transaction on Form 4. On 11/15/2025, 229 shares of common stock were withheld by Quanterix solely to cover tax obligations when 777 restricted stock units vested. After this tax withholding, the reporting person beneficially owns 86,206 shares of Quanterix common stock, which includes 85,429 restricted stock units that may convert into shares over time.
Quanterix Corp (QTRX) reported an insider equity transaction by its President & CEO, who is also a director. On 11/15/2025, 1,242 shares of common stock were withheld under transaction code "F", meaning the shares were retained by the company solely to cover tax obligations triggered by the vesting of 2,480 restricted stock units (RSUs). Following this tax withholding, the reporting person beneficially owns 510,200 shares of Quanterix common stock, which includes 216,606 RSUs.
Quanterix Corporation reported changes to its Board of Directors. Long-time directors Paul Meister and David Walt, Ph.D. retired from the Board and all its committees, and their departures were stated as not arising from any disagreement with the company’s operations, policies, or practices.
The Board appointed Garret Hampton, Ph.D., as a Class II director with a term expiring at the 2028 annual meeting, and Alan Sachs, M.D., Ph.D., as a Class I director with a term expiring at the 2027 annual meeting. Dr. Hampton will serve on the Audit and Compensation Committees, while Dr. Sachs will serve on the Compensation Committee.
Both new directors will receive an annual cash retainer of $50,000 plus additional committee retainers. Each will receive an initial restricted stock unit grant equal to 0.1% of Quanterix’s outstanding common shares on the grant date, vesting over three years, and ongoing annual RSU grants equal to 0.05% of outstanding shares, vesting after one year.
Quanterix Corporation (QTRX) reported Q3 2025 results with total revenues of $40.2 million, up from $35.8 million a year ago, driven by stronger product revenue of $26.2 million versus $19.7 million. Service and other revenue was $14.0 million, roughly flat year over year. Gross profit was $17.2 million compared with $20.2 million, as costs rose with the expanding business.
The company recorded a net loss of $33.5 million (vs. $8.4 million), reflecting higher selling, general and administrative expenses of $39.1 million, $7.2 million of impairment and restructuring costs, and $5.2 million of Akoya acquisition-related costs. Year-to-date operating cash flow used was $60.8 million. Cash and cash equivalents were $38.3 million and marketable securities $96.5 million at September 30, 2025.
Quanterix closed the Akoya Biosciences acquisition on July 8, 2025, with total consideration of $151.0 million, including $49.2 million in stock, $18.9 million in cash to shareholders, $82.1 million to extinguish debt, and recognized $121.8 million of acquired intangible assets and $23.5 million of goodwill. The quarter included $1.2 million of non-cash revenue from amortizing an acquired off‑market contract liability.
Quanterix Corporation (QTRX) furnished an Item 2.02 update announcing financial results for the third quarter ended September 30, 2025. The company provided an earnings press release and accompanying presentation slides as exhibits. The information in this item, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.
Exhibits include: 99.1 Earnings Release (November 10, 2025) and 99.2 Earnings Call Slides. The report was signed by Chief Financial Officer Vandana Sriram.